Roche turns to a Harvard upstart out of George Church’s lab to construct AAV 2.0 model vectors — a key part of building the gene therapy pipeline

For a gene therapy tech upstart that launched out of stealth mode just 5 months ago with big goals and not a tremendous amount …

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Roche turns to a Har­vard up­start out of George Church’s lab to con­struct AAV 2.0 mod­el vec­tors — a key part of build­ing the gene ther­a­py pipeline